Enhabit, Inc. (EHAB) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
Despite some positive financial metrics such as revenue growth and improved EBITDA margins, the earnings call reveals concerns over Medicare revenue decline, cost structure challenges, and economic uncertainty. The Q&A section highlights unclear management responses on key issues, adding to uncertainty. The strategic plan outlines growth, but potential headwinds from regulatory changes and payer renegotiations remain. Without clear guidance, the stock price is likely to remain stable, leading to a neutral sentiment.
Key Financial Performance
Home Health Total Admissions Up 3.6% year-over-year, with census increasing 3.7%. Normalized for closed branches, admission growth was 4.3% year-over-year. Fee-for-service Medicare census stabilized with a 1.4% year-over-year decline compared to a 14.1% decline in Q3 2024.
Non-Medicare Admissions Up 10.4% year-over-year. Managed payer mix resulted in a 2.8% increase in non-Medicare revenue per visit year-over-year.
Hospice Total Admissions Grew 1.4% year-over-year. Normalized for closed branches, admissions were up 3%. Census grew 12.6% year-over-year.
Consolidated Net Revenue $263.6 million, an increase of $10 million or 3.9% year-over-year. Growth driven by Hospice segment with 20% revenue growth.
Consolidated Adjusted EBITDA $27 million, an increase of $2.5 million or 10.2% year-over-year. Adjusted EBITDA margin expanded to 10.2%, up 50 basis points year-over-year.
Home Health Revenue $200.5 million, down $0.5 million or 0.2% year-over-year. Without payer renegotiation disruptions and branch closures, revenue would have been $3 million higher, reflecting 1% growth year-over-year.
Home Health Adjusted EBITDA $33.9 million, down $2.6 million or 7.1% year-over-year. Sequentially down $5.4 million or 13.7% due to margin compression from lower unit revenues and higher unit costs.
Hospice Revenue $63.1 million, up $10.5 million or 20% year-over-year. Growth driven by 12.6% increase in census and unit revenue growth.
Hospice Adjusted EBITDA $17.2 million, up $7.2 million or 72% year-over-year. Adjusted EBITDA margin improved by 830 basis points to 27.3%.
Home Office Expenses $24.1 million, down $2.3 million sequentially. Represented 9.1% of revenues in Q3 compared to 9.9% in the prior quarter.
Net Debt to Adjusted EBITDA Leverage 3.9x in Q3 2025, down from 5.4x in Q4 2023. Annualized cash interest expense reduced by approximately $19 million compared to Q4 2023.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Visits per episode management pilot: Initiated in mid-August in 11 branches, showing promising results with a decline in total visits per episode from approximately 15 to 13. Expanded to 83 additional branches in October, with full rollout expected by November.
Payer renegotiations: Achieved a low double-digit increase in per visit rate effective August 15, 2025, and successfully renegotiated another national payer contract in Q3 without disrupting patient access or census.
De novo strategy: Opened 2 new locations in Q3, totaling 6 year-to-date, with a seventh location opened in October. On track to open 10 de novos in 2025.
Home health admissions and census: Home health total admissions grew 3.6% year-over-year, with census increasing 3.7%. Non-Medicare admissions rose 10.4%, and non-Medicare revenue per visit increased by 2.8%.
Hospice segment growth: Achieved record revenues with 20% year-over-year growth and 12.6% census growth. Adjusted EBITDA for the segment grew over 70% year-over-year.
Cost management: Home office expenses improved by $2.3 million sequentially, reducing to 9.1% of revenues in Q3 from 9.9% in the prior quarter.
Financial health improvement: Reduced net debt to adjusted EBITDA leverage to 3.9x in Q3 2025 from 5.4x in Q4 2023. Annualized cash interest expense lowered by approximately $19 million compared to Q4 2023.
CMS 2026 home health rule mitigation: Focused on strategies to mitigate pricing headwinds, including advanced visit per episode management and cost structure optimization.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
CMS 2026 Home Health Rule: The proposed cuts in the CMS 2026 home health rule could reduce patient access to home health care, which is a cost-effective and patient-preferred option. This poses a risk to revenue and patient outcomes if finalized.
Payer Renegotiation Disruptions: Renegotiations with national payers caused disruptions in admissions and census early in the quarter, impacting revenue and operational stability. Although resolved, such disruptions could recur.
Medicare Revenue Decline: Fee-for-service Medicare census continues to decline, with a 1.4% year-over-year drop. This ongoing shift to Medicare Advantage could pressure revenue and profitability.
Cost Structure Challenges: Efforts to manage costs, such as advanced visit per episode management, are critical to offset uncontrollable rate disruptions. However, these measures may not fully mitigate financial pressures.
Economic and Regulatory Uncertainty: The dynamic operating environment, including potential CMS rate adjustments and broader economic conditions, creates uncertainty for strategic planning and financial performance.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance: Full year revenue is expected to be in the range of $1.058 billion to $1.063 billion.
Adjusted EBITDA Guidance: Full year adjusted EBITDA is projected to be in the range of $106 million to $109 million.
Adjusted Free Cash Flow Guidance: Full year adjusted free cash flow is anticipated to be in the range of $53 million to $61 million.
CMS 2026 Home Health Rule: The company is focused on mitigating potential pricing headwinds from the CMS 2026 home health final rule through various strategies already deployed. More details will be provided in Q1 2026.
Visits Per Episode Optimization: The company is rolling out a visits per episode optimization strategy across all branches by the end of November 2025, aiming to reduce visits per episode to offset potential rate reimbursement headwinds.
De Novo Strategy: The company plans to open a total of 10 de novo locations in 2025, with 7 already opened by October.
Debt Reduction: The company has reduced total debt by $100 million since Q4 2023 and plans to continue deleveraging its balance sheet.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you provide details on the rate increase from the new payer innovation contract in November and the pipeline of upcoming contracts?
A:The first national payer innovation contract renewal was completed, but specific updates on the rate increase were not disclosed. Regional agreements will come up for renewal next year, while future national agreements are expected towards the end of next year or early 2027.
Q:What contributed to the improvement in the G&A line, and is there more room for cost reduction?
A:The improvement was due to headcount reductions and insourcing capabilities from third-party vendors, resulting in $1 million to $1.5 million in sequential G&A improvement. This improvement is considered durable, with potential for further cost reductions.
Q:Should we expect a similar increase in hospice average length of stay from Q3 to Q4 this year due to seasonality?
A:Seasonality may cause some increase, but the holiday period is unpredictable as some patients delay electing hospice care until after the holidays. Additional resources have been added to extend outreach during this time.
Q:How long is the re-contracting cycle for payer innovation contracts?
A:The re-contracting cycle is contract-specific, with most contracts lasting around three years, though some are two years.
Q:Can you provide insights on labor trends and wage inflation expectations for 2026?
A:There has been an increase in the applicant pool for nursing and therapy, as well as headcount in clinical capacity for Home Health and Hospice. Wage inflation is expected to return to a normal merit increase of around 3%, with occasional market-level adjustments, particularly in therapy.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the rate increase from the new payer innovation contract, citing its status as a payer innovation. Additionally, the response to the question about seasonality in hospice length of stay was somewhat vague, emphasizing unpredictability without providing concrete data.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
CMS home
CMS rate
GA cost
Home Health
access
admission census
bank debt
branch admission
census payer
census unit
census volume
challenge
date
day unit
debt leverage
digit
environment
episode lever
episode pilot
headwind
increase margin
increase visit
leader
margin compression
member
novos
payer disruption
payer renegotiation
period
prepayment
priority
rate rule
reach source
record
renegotiation disruption
resource
revenue improvement
revenue unit
unit revenue
update
EHAB Transcript
Enhabit, Inc. (EHAB) Presents at Bank of America Home Care Conference Transcript
Neutral12-9
Enhabit, Inc. (EHAB) Presents at UBS Global Healthcare Conference 2025 Transcript
Neutral11-11
Enhabit, Inc. (EHAB) Q3 2025 Earnings Call Transcript
Unknown11-7
Despite some positive financial metrics such as revenue growth and improved EBITDA margins, the earnings call reveals concerns over Medicare revenue decline, cost structure challenges, and economic uncertainty. The Q&A section highlights unclear management responses on key issues, adding to uncertainty. The strategic plan outlines growth, but potential headwinds from regulatory changes and payer renegotiations remain. Without clear guidance, the stock price is likely to remain stable, leading to a neutral sentiment.
Enhabit, Inc. (EHAB) Q2 2025 Earnings Call Transcript
Positive8-8
The earnings call summary and Q&A indicate strong financial performance, with improved EBITDA margins, cost savings, and successful payer contract renegotiations. Despite concerns about potential rate cuts, management has strategies in place to mitigate negative impacts. The reaffirmed revenue guidance and positive cash flow conversion further support a positive outlook. The Q&A section reveals confidence in overcoming challenges, which aligns with the positive sentiment from the earnings call. Overall, the financial health and strategic initiatives suggest a positive stock price movement over the next two weeks.
EHAB Slides
EHAB Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
